BusinessHealthMedical DevicesPharmaceuticalScienceTechnologyTop Stories

Global Primary Sclerosing Cholangitis Market Outlook on Key Growth Trends and Forecast Until 2026 By Acorda Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), NGM Biopharmaceuticals (US), Intercept Pharmaceuticals & Others

The Primary Sclerosing Cholangitis market research report is a huge research database spread crosswise over different pages with various tables, diagrams, and figures in it. The most recent information has been conveyed, alongside accumulation of reasonable data, quantitative and subjective estimation by industry specialists and the commitment from industry relates over the value chain. This report exhibits a nearby watch on the commanding organizations, types, applications, grouping, and measure, just as SWOT analysis and business environment in the pharmaceutical  industry. The report will help market pioneers/new participants in global Primary Sclerosing Cholangitis market with data about this market and its physical foundation fragments. It offers a brief perspective by the information identified with the Primary Sclerosing Cholangitis market research report

The Primary Sclerosing Cholangitis market research report will enable the clients to comprehend the aggressive scene to acquire bits of knowledge and better position their organizations and make reasonable arrangements utilizing the go-to-showcase techniques. The report will likewise enable the partners to comprehend the crucial movement of the market and give them data on the key market drivers, difficulties, and openings. The report gives a broad stage offering different open ways for various affiliations, firms, and new affiliations. This report contains a prologue to build up the procedure by fighting amidst adversaries and give better associations with the clients.

Market Analysis: 

Global Primary Sclerosing Cholangitis Market is expected to rise gradually to an estimated value of USD 157.13 million by 2026, registering a CAGR of 3.7% in the forecast period of 2019-2026 with the annual sales of USD 117.5 million in the year of 2018. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients.

Ask For Complimentary Sample PDF | Request At  https://databridgemarketresearch.com/request-a-sample/?dbmr=global-primary-sclerosing-cholangitis-market

Key Market Competitors: 

Few of the major competitors currently working in the primary sclerosing cholangitis market are Acorda Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), NGM Biopharmaceuticals (US), Intercept Pharmaceuticals, Inc. (US), Dr. Falk Pharma GmbH (Germany), ALLERGAN (Ireland), Takeda Pharmaceutical Company Limited. (Japan), DURECT CORPORATION (US), Conatus Pharmaceuticals, Inc. (US), Sirnaomics, Inc. (US), and HighTide Therapeutics Inc. (China), Glenmark (India), Impax Laboratories, LLC (US), Mylan N.V. (US), Teva Pharmaceuticals Industries Ltd. (Israel) and few among others.

Market Drivers

Rise in incidence and prevalence rate of liver failure and bile cancer associated with PSC.

Large No. of pipeline molecules is expected to drive the growth of the market.

Market Restraints

Withdrawal of novel molecules from late stage clinical trials will restrain the growth of the market.

Organ transplantation remains the alternative which is associated with many risk factors like relapse of the disease.

Lack of skilled expertise in remote areas

Fewer Government initiatives taken in this direction.

Table of Contents

1. Introduction
2. Market Segmentation
3. Market Overview
4. Executive Summary
5. Premium Insights
6. Global, By Component
7. Product Type
8. Delivery
9. Industry Type
10. Geography
10.1. Overview
10.2. North America
10.3. Europe
10.4. Asia-Pacific
10.5. South America
10.6. Middle East & Africa
11. Company Landscape
12. Company Profiles
13. Related Reports

Get detailed toc @ https://databridgemarketresearch.com/toc/?dbmr=global-primary-sclerosing-cholangitis-market

Segmentation: 

By Type

Classic PSC

Small-duct PSC

PSC associated with autoimmune hepatitis

By Treatment Type

Ursodeoxycholic acid

Obeticholic Acid

Methotrexate

Corticosteroids

Others

By Symptom Control

Antihistamines

Cholestyramine

Antibacterials

Opioid Antagonists

Colestipol

Others

By End- User

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Geography

North America

US.

Canada

Mexico

South America

Brazil

Argentina

Rest of South America

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Turkey

Belgium

Netherlands

Switzerland

Rest of Europe

Asia-Pacific

Japan

China

South Korea

India

Australia

Singapore

Thailand

Malaysia

Indonesia

Philippines

Rest of Asia Pacific

Middle East & Africa

South Africa

Egypt

Saudi Arabia

United Arab Emirates

Israel

Rest of Middle East & Africa

Key Developments in the Market:

On 19th January, 2016, Acorda Therapeutics, Inc. announced that it entered into an agreement to acquire Biotie Therapies Corp. According to the agreement, the company will acquire the four pipeline products that include BTT1023, a fully human monoclonal antibody in Phase 2 development for treatment of primary sclerosing cholangitis (PSC) which will help company to grow.

On 27th March, 2019, Gilead Sciences, Inc. announced the company’s research and development programs in primary sclerosing cholangitis (PSC) will be presented at The International Liver Congress™ 2019 in Vienna. Currently the novel molecule, Cilofexor has not get the approval but once it gets approval it will generate the revenue for the company and contribute towards the growth of the market.

Competitive Analysis: 

Global primary sclerosing cholangitis market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of primary sclerosing cholangitis market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Inquiry For Customize Report With Discount at : https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-primary-sclerosing-cholangitis-market

Customization of the Report:

All segmentation provided above in this report is represented at country level

All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: Sopan.gedam@databridgemarketresearch.com

 

 

 

 

Tags

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *